- Home
- RPTX vs ADAG Comparison
RPTX vs ADAG Comparison
Compare RPTX & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPTX | ADAG |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | Canada | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.4M | 84.8M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RPTX | ADAG |
|---|---|---|
| Price | $2.56 | $1.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $3.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 1.4M | 44.4K |
| Earning Date | 11-14-2025 | 08-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,870,000.00 | $103,204.00 |
| Revenue This Year | N/A | $6,983.06 |
| Revenue Next Year | $3,233.33 | $36.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.89 | $1.30 |
| 52 Week High | $2.66 | $3.16 |
Technical Indicators
Market Signals| Indicator | RPTX | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 71.90 | 41.66 |
| Support Level | $2.56 | $1.75 |
| Resistance Level | $2.66 | $1.83 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 81.55 | 0.00 |
Price Performance
Historical ComparisonAbout RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.